Avio Smart Market Stack Limited reported a 160% year-on-year increase in revenue to ₹103.96 Cr for FY26, driven by the success of its diversification strategy into new verticals. Profit after tax surged 240% to ₹5.94 Cr from ₹1.75 Cr in the previous year, while reserves turned positive at ₹3.72 Cr against a negative balance of ₹2.20 Cr in FY25. The company submitted its investor presentation to the exchanges on June 12, 2026, disclosing these financial metrics.

The performance was anchored by the Agri Supply Chain & Technologies division, which emerged as the largest business vertical with revenue of ₹60.69 Cr, contributing approximately 58% of the total revenue. This segment was a new vertical in FY26. The Financial Inclusion & Digital Services division generated ₹40.72 Cr, a growth of 7.7% from ₹37.79 Cr in FY25, accounting for 39% of the revenue. The Diagnostics & Healthcare division remains in the early stages, while the Others segment contributed ₹2.55 Cr.

Financial Performance

The company’s financial turnaround was marked by a significant improvement in profitability metrics across its diversified platforms. The segment results show that the Agri Supply Chain division contributed ₹4.71 Cr, while the Financial Inclusion division added ₹0.86 Cr to the overall profitability.

Strategic Overview

Avio Smart Market Stack Limited operates across three primary divisions: Financial Inclusion & Digital Services, Agri Supply Chain & Technologies, and Diagnostics & Healthcare. The Financial Inclusion division serves approximately 40 million rural people across 5,000 villages in 10 states through partnerships with 7 public and regional rural banks. The Agri Tech division is building capabilities on the existing banking network, with goals to digitally onboard 20 million farmers and open 1,000 smart agri-stores. The Diagnostics division has partnered with Huwel Lifesciences to develop a molecular diagnostics platform with over 140 products.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE855F01042/146f4be275034d79.pdf

Avio Smart Market Stack Limited has initiated strategic discussions with Medici Institute of Medical Sciences (MIMS), Hyderabad, to explore opportunities for research collaboration, clinical validation, and adoption of advanced molecular diagnostic technologies. The engagement aims to strengthen disease detection, improve clinical decision-making, and enhance healthcare outcomes across India. This move is part of bartronics 's strategy to build a scalable Diagnostics & Healthcare business through its strategic partnership with Huwel Lifesciences.

Huwel Lifesciences, ASMS' strategic molecular diagnostics partner, showcased its portfolio of indigenous diagnostic technologies during the discussions. The portfolio includes solutions for tuberculosis, multidrug-resistant tuberculosis (MDR-TB), sepsis, HPV screening, hepatitis, antimicrobial resistance (AMR) detection, respiratory diseases, and environmental surveillance. The company highlighted its fully integrated diagnostics platform, which spans assay development, reagent manufacturing, instrumentation, software, and data management.

The discussions focused on collaborative research, clinical validation studies, real-world evidence generation, and opportunities for the adoption and deployment of Huwel's diagnostic technologies within Medici's healthcare ecosystem. The organizations also explored the possibility of pilot programs and product evaluations across selected departments to assess their impact on routine diagnostic workflows.

Strategic Objectives

Mr. Vidyasagar Reddy, Managing Director, Avio Smart Market Stack, stated that the company has made a significant commitment to building a scalable Diagnostics & Healthcare business through its partnership with Huwel Lifesciences. He emphasized that while scientific validation is important, the objective is equally focused on accelerating real-world adoption of these technologies by leading healthcare institutions. The engagement with Medici creates opportunities for research collaboration, clinical evaluation, and potential deployment of Huwel's diagnostic solutions.

Dr. Shesheer Kumar, Founder and Director, Huwel Lifesciences, noted that the future of healthcare innovation depends on close collaboration between technology developers, clinicians, and research institutions. He expressed that Medici's strong research capabilities and clinical expertise make it an ideal partner for advancing scientific validation and evaluating the impact of innovative diagnostics in real-world healthcare settings.

Key Diagnostic Areas

ASMS is actively building market access channels for advanced diagnostic technologies through partnerships with healthcare institutions, government programs, research organizations, and industry stakeholders. The company is working to accelerate validation, adoption, procurement, and large-scale deployment of indigenous diagnostic solutions across India and international markets.